Curecoin is a new SHA-256 based cryptocurrency with a big vision, that is - Curing Cancer, Alzheimer's, Huntington's, preventing viruses, and designing next-level of pharmaceuticals. Curecoin can be earned with both GPU and CPU. Folders use high-end GPUs and CPUs to fold proteins, earning a proportional amount of coins set-aside for their contributions. SHA-256 ASIC Miners could still get along by mining Curecoin as usual which will further secure the blockchain and the network. Whether you are heavily-invested in ASIC equipment or still have GPUs and CPUs, you can participate. Due to the nature of folding (diverse, constantly changing, not easily predictable), GPUs and CPUs will both always be relevant, so an investment in consumer hardware isn't wasted. Curecoins go to three main areas: Folders, Miners, and Developers. The folders get 76% of the total coins (80% of the coins distributed per day). SHA256 miners get 19% of the total coins (20% of the coins distributed per day). 2% of the total funds are distributed to people who donated to project development. The other 3% is dedicated to Curecoin developers, and will be used for paying for development costs (such as hiring professional programmers, paying for infrastructure, etc.), and for giving back to the community (folding hardware giveaways, faucets, covering 0% mining pools, etc.).
Ice Rock Mining is here to bring bitcoin mining to the investment world. We believe bitcoin has a long and significant role in the new monetary system that is forming. Our goal is to raise capital and scale our mining business; we are currently in operation and already delivering returns to our investors. With Ice Rock, investors become our partners and share in the realization of profits, while assuring themselves a stable and passive income. Because of our efficiencies, we are able to operate on lower costs and thereby pass those savings on to our investors. With today’s hashrates, our ROI to investors is over 200% per year, and could increase if the price of bitcoin appreciates.